Press Releases VYNE Therapeutics Inc.

Equities

VYNE

US92941V3087

Delayed Nasdaq Other stock markets 15:02:02 09/05/2024 BST			5-day change	1st Jan Change
2.72 ^USD	+0.02%		+8.82%	+16.76%

02:23pm	Earnings Flash (VYNE) VYNE THERAPEUTICS Posts Q1 Revenue $98,000	MT
05-06	VYNE Therapeutics Says US FDA Clears its Investigational New Drug Application for Potential Autoimmune Treatment	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

VYNE Reports First Quarter 2024 Financial Results and Provides Business Update	01:02pm	AQ
VYNE Therapeutics Announces FDA Clearance of IND Application for VYN202, a Novel BD2-Selective BET Inhibitor	05-06	AQ
VYNE Therapeutics Announces Oral Presentations for VYN201 at the 2024 Society for Investigative Dermatology (SID) Annual Meeting	05-01	AQ
VYNE Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference	03-19	AQ
VYNE Reports 2023 Fourth Quarter and Year-End Financial Results and Provides Business Update	02-29	AQ
VYNE Therapeutics to Present Results of the Phase 1b Trial for VYN201 at the 2024 Global Vitiligo Foundation Annual Scientific Symposium	02-27	AQ
VYNE Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference	02-21	AQ
VYNE Therapeutics Announces Positive Biomarker Data from Successful Phase 1b Trial of VYN201 for the Treatment of Vitiligo	01-10	AQ
VYNE Therapeutics Appoints Christine Borowski, Ph.D., to its Board of Directors	01-03	AQ
VYNE Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update	11-13	AQ
VYNE Therapeutics to Host Virtual R&D Day Event on November 9, 2023	11-07	AQ
VYNE Therapeutics Announces Closing of Previously Announced Private Placement of $88.2 Million	11-01	AQ
VYNE Therapeutics Reports Positive Results from Preclinical Models for Oral BD2-Selective BET Inhibitor VYN202	30/10/23	AQ
VYNE Therapeutics Announces Private Placement of $88 Million	30/10/23	AQ
VYNE Therapeutics Announces Positive Data from Phase 1b Trial for Novel BET Inhibitor VYN201 in Patients with Nonsegmental Vitiligo	30/10/23	AQ
VYNE Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference	06/09/23	AQ
VYNE Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update	14/08/23	AQ
VYNE Therapeutics to Attend BIO International Convention	18/05/23	AQ
VYNE Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update	11/05/23	AQ
University of Dundee : Spinout agrees potential $50 million deal	03/05/23	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases VYNE Therapeutics Inc.

Equities

VYNE

US92941V3087

Press Releases

Filters